Ependymoma
📧 Sign up to get email alerts when something new happens for Ependymoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-18Clinical Trial Results: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers [Phase 2]
Phase 2 trial of nivolumab for recurrent rare CNS cancers (including medulloblastoma and ependymoma) was terminated with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors [Phase 2]
Phase 2 clinical trial assessing memantine to prevent cognitive late effects in children receiving cranial radiation for localized brain tum…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Methionine PET/CT Studies In Patients With Cancer [Phase 2]
Phase 2 methionine-based PET/CT imaging studies in patients with various cancers; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
An exploratory study evaluating the effects of radiation therapy in pediatric patients with central nervous system tumors; the study include…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
This trial update describes a pediatric brain tumor study using cerebrospinal fluid cell-free tumor DNA; the study was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma [NA]
The document reports a clinical trial update for an individualized treatment plan in children and young adults with relapsed medulloblastoma…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors [Phase 1]
Phase 1 clinical trial evaluating B7-H3–specific CAR T cell therapy delivered locoregionally for diffuse intrinsic pontine glioma/diffuse mi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating ensartinib for patients with relapsed or refractory ALK- or ROS1-genomic a…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma [Phase 1]
Phase 1 trial of pembrolizumab in pediatric patients with recurrent or refractory high-grade gliomas, including diffuse intrinsic pontine gl…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma [Phase 1]
A Phase 1 pediatric trial of SurVaxM for progressive or relapsed medulloblastoma, high-grade glioma, ependymoma, and newly diagnosed diffuse…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG [NA]
This ClinicalTrials.gov entry reports ongoing pediatric trials of Optune (Tumor Treating Fields) for malignant glioma and ependymoma, and in…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma [Phase 1]
A Phase 1 trial evaluating HER2-directed CAR T cells in pediatric patients with ependymoma.
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating IDH1-mutant tumors for response to ivosidenib; results for recurrent and refractory solid tumors, l…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Rare CNS Tumors Outcomes &Risk
A National Cancer Institute clinical trial update reports outcomes and risks for rare central nervous system tumors, including meningioma, e…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications [Phase 1, Phase 2]
Clinical trial update for PLX038 in primary CNS tumors with MYC or MYCN amplification; Phase 1/2 studies are currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors [Phase 1]
Phase 1 clinical trial evaluating ONC206 for newly diagnosed and recurrent diffuse midline gliomas and other recurrent malignant CNS tumors;…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) [Phase 1]
This clinical trial update describes an ongoing Phase 1 study evaluating adoptive cellular therapy immunotherapy for several pediatric malig…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma [Phase 1, Phase 2]
This clinical trial update describes a phase 1/2 study of PEP-CMV in combination with nivolumab for newly diagnosed and recurrent diffuse mi…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma [Phase 1]
Phase 1 clinical trial evaluating IL13Ralpha2-CAR T cells for treating leptomeningeal metastasis, glioblastoma, ependymoma, and medulloblast…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 [Phase 1]
Phase 1 clinical trial update on rQNestin34.5v.2 for recurrent malignant glioma, including glioblastoma and related gliomas, with status cur…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors [Phase 2]
A Phase 2 clinical trial update describes an antiangiogenic therapy for children with recurrent medulloblastoma, ependymoma, ATRT, and other…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors [Phase 2]
A Phase 2 clinical trial of intratumoral DNX-2401 for pediatric high-grade brain tumors is not yet recruiting. The study targets high-grade …
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod [Phase 1]
Phase 1 trial evaluating a tumor antigen peptide vaccine with imiquimod for children with recurrent ependymoma; the study status is terminat…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma [Phase 2]
An update on an ongoing Phase 2 clinical trial evaluating 131I-Omburtamab for recurrent Medulloblastoma and recurrent Ependymoma. The trial …
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: B7-H3.CD28Z.CART in CNS Neoplasms [Phase 1]
A Phase 1 clinical trial evaluating B7-H3.CD28Z.CART for central nervous system neoplasms is currently not yet recruiting.